Martina Gasparro

MD Oncology Resident in Turin at @SLuigiGonzagaHospital / @GustaveRoussy 🇮🇹 🇫🇷

[Jordi Remon @JordiRemon]

Treatment landscape of early-stage NSCLC is evolving very fast. We review current SoC with IO and targeted therapies(TT) and future challenges:
-Neoadj vs periop?
-IO in borderline resectable
-How to ⬆️pCR
-Role of TT..
@peters_solange @g_mountzios
https://t.co/d7DXBbYkXI

[Martina Gasparro @maarggi1]

The two days international clinical #research course promoted by @AIOMtweet & @ASCO has just ended! Thank you, to the faculty & all partecipants for this super opportunity in the wonderful Rome 🇮🇹 🇺🇸

[Martina Gasparro @maarggi1]

Bringing the whole School of Medical Oncology of Turin to a monastery in the Alps: learning, debating, and engaging with oncology’s key opinion leaders, while skiing, have a wine tasting and meeting Chris Bangle. Thank you #silvianovello #school #oncology

[Martina Gasparro @maarggi1]

Super first day at the @myESMO Lung Cancer PRP in Barcelona! 🫁 Inspiring talks on international collaboration, molecular pathology, liquid biopsy, and the MTD approach in #NSCLC.
Thank you to the faculty @DrJNaidoo @Piuchagarrido @EnriquetaFelip @UmbertoMalapel1 @Tony_Calles

[Martina Gasparro @maarggi1]

Closing (temporarily) an unforgettable chapter at Gustave Roussy. Thank you to all the incredible people, from the chefs to my co-interns, who made this journey so special. Merci Paris, à très bientôt 🇫🇷 @dplanchard @JordiRemon @BenjaminBesseMD @LeQuartzy @brunella43665

[d.planchard @dplanchard]

The @GustaveRoussy Thoracic Oncology 031 dream team (France, Canada, Italy…) is leaving after 6–12mo of sharing, happiness, and invaluable support in both clinical work and research.
We wish our amazing Fellows all the best in their future endeavors and see you soon! @maarggi1

[Martina Gasparro @maarggi1]

@dplanchard @GustaveRoussy @LeQuartzy @brunella43665 merci à tous 🤍

[Roberto Iacovelli @DrIacovelli]

New way to treat pts with #MIBC not eligible to cisplatin presented in the plenary session at #ESMO25. EV303 showed the correct way using EV+P as perioperative strategy. The question is now...should we continue in offering surgery? @tompowles1
@OncoAlert @GUOncologyNow @Uromigos

[Martina Gasparro @maarggi1]

From molecular targets to meaningful outcomes, where science meets care — advancing with targeted therapies together. 🎯 #Oncology #PrecisionMedicine #ESMO25 🎯 🫁 @myESMO

[Roberto Ferrara @RobertoFerrara_]

EORTC Lung Cancer Group community at #ESMO25.
Young and Early Career Investigator connecting beyond institutions, countries and generations are the energy, innovation and the voice that keeps this community grow
@MOcchipintiMD @JcbenitezMD @M_Tagliamento @ACortelliniMD

[Jordi Remon @JordiRemon]

Zipalertinib in EGFRex20ins NSCLC reported 31% of intracranial ORR 🧠. Today crowded space of TKI for EGFRex20ins. New SoC? Best sequence? Brain activity and toxicity relevant for 1st Line decision. #ESMO25

[Benjamin Besse @BenjaminBesseMD]

ALEX final OS:
- crizo arm dragged down by <50% getting next-gen ALK. Lack of crossover really hurts.
- 5-yr OS with alectinib ≈ 5-yr PFS with lorlatinib (CROWN), but only 18% got lorla post alect — we still don’t know the optimal sequence. #ESMO25

[Jordi Remon @JordiRemon]

HER2 TKI for HER2m NSCLC are real again (new zombies) with outstanding activity. What is best TKI? Toxicity will count. Next challenge: TKI vs Trastuzumab in 1st line? Best sequentil approach? Combo TKI and Chemo? #ESMO25.

[Yakup Ergün @dr_yakupergun]

Unresectable stage III non-small-cell lung cancer: state of the art and challenges

Great review👇

https://t.co/PPifVC0ygg

[Jordi Remon @JordiRemon]

In 1st L, subcut. amivantamab ➕ CT works in EGFR ex20ins 🫁 similar to iv amiva. Despite sc amiv. reduces infusion reactions,the skin/paronychia EGFR-related toxicity remains the most common.Perhaps future in 1st L🔮EGFRex20ins TKI —> sc ami + TKI (TVE risk?)—> Chemo #WCLC2025

[Jordi Remon @JordiRemon]

In unresectable sIII NSCLC 🫁several strategies tested to ⬆️ the SoC PACIFIC🌊outcomes, such as IO+CTRT. EA5181 trial confirms that CTRT+IO, similar to PACIFIC2 & CheckMate73L trials, not ⬆️ outcomes.
Other ongoing trials awaited. Is future: induction CT+IO —>RT+/- CT —> Durva?🔮

[giovanni farinea @FarineaGiovanni]

Happy to present my poster on #PARPi and #IO synergism in #MPM: Results from the UNITO trial. #ELCC25 @myESMO @PassigliaFra @lullirighi

[Martina Gasparro @maarggi1]

We love our mentors at @GustaveRoussy!
Thank you @JordiRemon #ELLC25

[d.planchard @dplanchard]

Great "CLUB031" meeting this morning with our young talents and @BenjaminBesseMD to discuss progress on the translational studies they are brilliantly carrying out at @GustaveRoussy ! What a pleasure to accompany them in their career in thoracic oncology...@ClaudiaParisi18

[Giuseppe Banna @gbanna74]

Grateful to the oncology residents at @unito for the warm welcome during their Didactic Week, fantastic initiative by Silvia Novello to learn, network & grow together.
Thanks to @LulieZumstein, @AAValsecchi & @O_Cantale for the flawless organization!
Loved their curiosity!